Narciclasine (Synonyms: (+)-Lycoricidinol, (+)-Narciclasine) |
| Catalog No.GC12491 |
Narciclasine is a plant growth regulator with antimitotic activity and pro-apoptotic property.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 29477-83-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Narciclasine is a plant growth regulator with antimitotic activity and pro-apoptotic property [1]. Narciclasine can interact with the ribosomal 60S subunit and inhibit peptide bond formation by preventing the 3' end of the donor substrate from binding to the peptidyl transferase center, thereby reducing protein synthesis [2]. Narciclasine has been widely used to induce mitochondrial membrane potential depolarization and eliminate pathogenic parasites[3].
In vitro, Narciclasine treatment for 48 hours significantly inhibited the viability of HCT116, MDA-MB-231, and HT-29 cells with IC50 values of 0.108µM, 0.0495µM, and 1.205µM, respectively[4]. Treatment of SCC-47 cells with 100nM of Narciclasine for 24 hours resulted in decreased expression of the mesenchymal markers N-cadherin and β-catenin and inhibited cell migration and invasion[5]. Treatment of BCG-823 cells with 1µM of Narciclasine for 24 hours inhibited the proliferation of BCG-823 cells, inhibited the levels of p-AKT and p-mTOR, and promoted apoptosis and autophagy[6].
In vivo, Narciclasine treatment via oral administration at a dose of 1mg/kg/week for seven weeks attenuated high-fat diet-induced obesity in mice, reduced fat mass accumulation, and enhanced mitochondrial respiration and fatty acid oxidation in skeletal muscle[7]. Daily intraperitoneal injection of Narciclasine (1mg/kg/day) for 14 days reduced VEGF-induced angiogenesis in mice[8]. Subcutaneous administration of Narciclasine (1mg/kg) 12h prior to intraperitoneal injection of zymosan A attenuated inflammation and blocked leukocyte adhesion and transendothelial migration in a mouse model of zymosan-induced peritonitis[9].
References:
[1] Ingrassia L, Lefranc F, Dewelle J, et al. Structure− activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents[J]. Journal of medicinal chemistry, 2009, 52(4): 1100-1114.
[2] Nair J J, van Staden J. Insight to the antifungal properties of Amaryllidaceae constituents[J]. Phytomedicine, 2020, 73: 152753.
[3] Gomes K S, Costa-Silva T A, Borges W S, et al. Antiparasitic Activity of Narciclasine and Evaluation of Its Effects on Plasma Membrane and Mitochondria of Trypanosoma cruzi[J]. ACS omega, 2025, 10(3): 3025-3032.
[4] Wang M, Liang L, Wang R, et al. Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cells[J]. Natural Products and Bioprospecting, 2023, 13(1): 27.
[5] Shieu M K, Ho H Y, Lin C C, et al. Narciclasine suppresses oral cancer metastasis by modulating cathepsin B and extracellular signal–related kinase pathways[J]. Biomedicine & Pharmacotherapy, 2023, 158: 114159.
[6] Yuan Y, He X, Li X, et al. Narciclasine induces autophagy-mediated apoptosis in gastric cancer cells through the Akt/mTOR signaling pathway[J]. BMC Pharmacology and Toxicology, 2021, 22(1): 70.
[7] Julien S G, Kim S Y, Brunmeir R, et al. Narciclasine attenuates diet-induced obesity by promoting oxidative metabolism in skeletal muscle[J]. PLoS biology, 2017, 15(2): e1002597.
[8] Bräutigam J, Bischoff I, Schürmann C, et al. Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2[J]. Journal of Molecular and Cellular Cardiology, 2019, 135: 97-108.
[9] Stark A, Schwenk R, Wack G, et al. Narciclasine exerts anti‐inflammatory actions by blocking leukocyte–endothelial cell interactions and down‐regulation of the endothelial TNF receptor 1[J]. The FASEB Journal, 2019, 33(8): 8771-8781.
| Cell experiment [1]: | |
Cell lines | H1299 cells |
Preparation Method | H1299 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were cultured in a humidified incubator at 37℃ with 5% CO2. Cells suspended in 100µl/ well medium were seeded in 96-well plates at a density of 5400 cells per well and cultured for 24 hours. Cells were treated with different concentrations of Narciclasine (0, 50, 100, 200, 400, 800, 1000, 1200, and 1400nM) for 48 hours. 20µl of MTT solution (5mg/ml) was added to each well, and the culture was continued for 4 hours at 37°C. The supernatant was discarded, 100µl DMSO was added to each well to dissolve methylene dye, and the absorbance at 570nm was measured. |
Reaction Conditions | 0, 50, 100, 200, 400, 800, 1000, 1200, and 1400nM; 48h |
Applications | Narciclasine treatment inhibited the cell viability of H1299 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | Eight-week-old male C57BL/6J mice were housed in a 12h light/12h dark cycle with free access to water. The mice were divided into two groups: fed with a normal diet (NCD) and a high-fat diet (HFD). NCD and HFD mice were treated with Narciclasine (1mg/kg/week) or vehicle by gavage once a week for 7 weeks starting from 10 weeks of age. Body weight and visceral and subcutaneous fat were analyzed. |
Dosage form | 1mg/kg/week for 7 weeks; p.o. |
Applications | Narciclasine treatment significantly reduced HFD-induced weight gain and, promoted the reduction of visceral and subcutaneous fat in mice. |
References: | |
| Cas No. | 29477-83-6 | SDF | |
| Synonymes | (+)-Lycoricidinol, (+)-Narciclasine | ||
| Chemical Name | (2S,3R,4S,4aR)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one | ||
| Canonical SMILES | C1OC2=C(O1)C(=C3C(=C2)C4=CC(C(C(C4NC3=O)O)O)O)O | ||
| Formula | C14H13NO7 | M.Wt | 307.26 |
| Solubility | ≥ 14.7mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2546 mL | 16.2729 mL | 32.5457 mL |
| 5 mM | 650.9 μL | 3.2546 mL | 6.5091 mL |
| 10 mM | 325.5 μL | 1.6273 mL | 3.2546 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *